1988 Volume 36 Issue Supplement2-Clinical Pages 831-840
NY-198, a newly developed quinolone, was given to 37 patients with urogenital infection: acute uncomplicated cystitis (AUC) 10, chronic complicated UTI (CCU) 23, prostatitis 3 and epididymitis 1.
Clinical efficacy in AUC, as rated by the Japanese UTI Drug Evaluation Criteria, was excellent in 7 and moderate in 3 of the 10 patients. The physicians' evaluation was excellent in 8 and good in 2. The efficacy rate was 100% in both evaluations.
Clinical efficacy in CCU was excellent in 6, moderate in 9, poor in 4 and unevaluable in 4 of 23 patients by the Japanese UTI Criteria.
The physicians' evaluation was: excellent in 8, good in 6, fair in 3 and poor in 6, the efficacy rate being 79% by the Japanese UTI evaluation and 61% by the physicians' evaluation.
The efficacy rate in prostatitis by the physicians' rating was 67%(excellent in 1, good in 1 and poor in 1 of 3 patients).
The physicians' evaluation in epididymitis was fair. A slight elevation of s-GOT and s-GPT, found in only 1 of 37 patients, soon normalized. Other subjective or objective side-effects were not found.
